The efficacy and safety of TKIs may associate with race, age, sex, body weight, drug dose, the duration of treatment, baseline AFP levels, disease etiology, BCLC stage, liver function, tumor burden in the liver, and disease extension, which should be considered when choosing a treatment option for aHCC. This evidence concerns the gene AFP and neoplasm.